---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039348"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:46:41.935262+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics Q2 2023 net loss $3.1M; highlights positive AD and ALS clinical data

## Summary
- Net loss of $3.1M ($0.31 per share) for Q2 2023 vs $3.4M loss in Q2 2022.
- Cash and equivalents $13.1M as of June 30, 2023, up from $5.9M at Dec 31, 2022.
- Positive PoC data for ld IL-2 in Alzheimer's: statistically significant MMSE improvement and reduced neuroinflammation.
- ALS study of COYA 302 halted disease progression at 24 weeks; pre-IND meeting with FDA planned for H2 2023.
- Appointed Dr. Fred Grossman as President/CMO and Arun Swaminathan as CBO.

## SEC filing metadata
- accession: 0000950170-23-039348
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/0000950170-23-039348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/coya-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039348
- JSON: https://secwatch.observer/filing/0000950170-23-039348.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039348.txt

## Key facts
- Earnings Releases
  Coya Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/0000950170-23-039348-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.